Comparison Lung Function and Quality of Life Between Azithromycin and Roxithromycin in Bronchiectasis Patients

Abstract

Objectives:  this study was aimed to compare lung function and quality of life after using Azithromycin and Roxithromycin in bronchiectasis patients.

Methods:  the study design was descriptive prospective study. Forty-five bronchiectasis patients were divided into two groups as followed: group 1 treatment with azithromycin (n = 23) and group 2 treatment with roxithromycin (n = 22). Lung function test (FEV1, FVC) and SGRQ score were collected at baseline and after treatment for 8 weeks. The outcomes were statistical analyzed.

Results:  The lung function test before treatment showed that FEV1 and FVC of group 1 were higher than those of group 2 but there was no statistical significance. At baseline, total SGRQ score of group 1 was lower than those of group 2, however, no statistical significance was found. Comparing between before and after treatment, there was no exacerbation of bronchiectasis in both groups. FEV1 after treatment was increased in group 1 compare to before treatment, however FEV1 after treatment in group 2 was lower than before treatment. For FVC, after treatment it increased in group 2 compare to before treatment but in group 1 FVC was lower than before treatment. The changes of FEV1 and FVC in each groups and between groups were not statistically significant. The SGRQ score after treatment significantly decreased in both groups but when compared between two groups there was no statistically significance.

Conclusions:  The lung function and quality of life after using Azithromycin and Roxithromycin in bronchiectasis patients were not different.